%0 Journal Article
%T Sustained remission of symptoms and improved health-related quality of life in patients with cryopyrin-associated periodic syndrome treated with canakinumab: results of a double-blind placebo-controlled randomized withdrawal study
%A Isabelle Kon¨¦-Paut
%A Helen J Lachmann
%A Jasmin B Kuemmerle-Deschner
%A Eric Hachulla
%A Kieron S Leslie
%A Richard Mouy
%A Alberto Ferreira
%A Karine Lheritier
%A Neha Patel
%A Ralph Preiss
%A Philip N Hawkins
%A on behalf of the Canakinumab in CAPS Study Group
%J Arthritis Research & Therapy
%D 2011
%I BioMed Central
%R 10.1186/ar3535
%X In this 48-week, phase 3 study, patients with CAPS received canakinumab 150 mg subcutaneously at 8-week intervals. All patients (n = 35) received canakinumab during weeks 1 through 8; weeks 9 through 24 constituted a double-blind placebo-controlled withdrawal phase, and weeks 24 through 48 constituted an open-label phase in which all patients received canakinumab. Patient and physician assessments of symptoms, levels of inflammatory markers, and HRQoL were performed.Rapid symptom remission was achieved, with 89% of patients having no or minimal disease activity on day 8. Responses were sustained in patients receiving 8-weekly canakinumab. Responses were lost during the placebo-controlled phase in the placebo group and were regained on resuming canakinumab therapy in the open-label phase. Clinical responses were accompanied by decreases in serum levels of C-reactive protein, serum amyloid A protein, and interleukin-6. HRQoL scores at baseline were considerably below those of the general population. Improvements in all 36-item Short-Form Health Survey (SF-36) domain scores were evident by day 8. Scores approached or exceeded those of the general U.S. population by week 8 and remained stable during canakinumab therapy. Improvements in bodily pain and role-physical were particularly marked, increasing by more than 25 points from baseline to week 8. Therapy was generally well tolerated.Canakinumab, 150 mg, 8-weekly, induced rapid and sustained remission of symptoms in patients with CAPS, accompanied by substantial improvements in HRQoL.Clintrials.gov NCT00465985Cryopyrin-associated periodic syndrome (CAPS) is one of the genetic autoinflammatory disorders that are characterized by recurrent bouts of systemic inflammation, resulting in fever, rash, and joint pain [1,2]. Most of these disorders are very rare; CAPS has an estimated prevalence of approximately 1 per million, and even the most common one, familial Mediterranean fever, affects only approximately 100,000 people
%U http://arthritis-research.com/content/13/6/R202